Quantcast

Latest Sirolimus Stories

2010-09-23 18:58:00

WASHINGTON, Sept. 23 /PRNewswire/ -- OrbusNeich today announced that six-month follow-up clinical trial data demonstrate the excellent safety profile and efficacy of the company's Genous Bio-engineered R stent in combination with a paclitaxel-coated balloon for the treatment of de novo coronary artery disease. The data were presented by Jochen Woehrle, M.D., University of Ulm, Germany, principal investigator of the study, in the first report clinical trial session at Transcatheter...

2010-09-21 20:27:19

Three-year data from the prospective, randomized LEADERS trial demonstrate the equivalence of a biolimus A9-eluting stent with a biodegradable polymer vs. a sirolimus-eluting stent with a durable polymer. The results will be presented at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. The study is to be presented by Patrick W. Serruys, MD, PhD, Professor of Interventional Cardiology at the Thoraxcenter,...

2010-09-21 11:54:58

A new drug-eluting stent design demonstrated superiority over a traditional drug-eluting stent at 6 months, according to a study led by Laura Mauri, MD, Associate Professor of Medicine, Brigham and Women's Hospital, Harvard Medical School (Boston, MA.) The study is being presented at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. "This new stent proved superior to a traditional drug-eluting stent for...

2010-09-21 11:52:11

Three-year data demonstrated that satisfactory clinical and safety outcomes of sirolimus eluting stents with a biodegradable polymer were sustained in a real world setting. The results were presented at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. "The three-year data from the CREATE study is further evidence that biodegradable polymers represent the future of stent design," said Yaling Han, MD, the...

2010-09-02 06:59:00

STOCKHOLM, September 2, 2010 /PRNewswire/ -- - Additional Analysis of 18 Month Data of the SORT OUT III Trial Provides Detail on Safety and Efficacy Outcomes in Patients With Diabetes, Acute Coronary Syndrome, or Treatment of Multiple Lesions Three new analyses of subgroups from the SORT OUT III study presented at the European Society of Cardiology (ESC) meeting in Stockholm, Sweden, provide additional detail on longer-term follow-up subgroup safety and efficacy outcomes in the...

2010-08-31 05:20:00

STOCKHOLM, August 31, 2010 /PRNewswire/ -- - The Publication of 10-Year Follow-Up Test Results on the First CYPHER(R) Sirolimus-Eluting Coronary Stent Patient Reveal the Stent's Outstanding Efficacy and Safety Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today at European Society of Cardiology in Stockholm that the results of follow-up tests undertaken ten years after the first patient was treated with...

2010-07-01 00:25:00

EAST HANOVER, N.J., July 1 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today that results of a Phase III study show Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival, or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET). The study, RADIANT-3 (RAD001 In Advanced Neuroendocrine Tumors), was presented at the 12th World...

2010-06-05 16:39:00

EAST HANOVER, N.J., June 5 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS) (1,2). In this study of 28 patients presented today at the 46th American Society of Clinical Oncology (ASCO) annual...

2010-06-03 00:20:00

EAST HANOVER, N.J., June 3 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today that a Phase III study of Afinitor® (everolimus) tablets plus best supportive care met its primary endpoint, showing the drug significantly extended progression-free survival, or time without tumor growth, in patients with advanced pancreatic neuroendocrine tumors (NET). The study, RADIANT-3 (RAD001 In Advanced Neuroendocrine Tumors), is part of the largest...

2010-05-25 08:02:00

PARIS, May 25, 2010 /PRNewswire/ -- - NEVO(TM), Incorporating RES TECHNOLOGY(TM), Continues to Support Excellent Safety and Efficacy Outcomes vs. the Taxus(R) Liberte(R) According to Data Presented at EuroPCR 2010 At 12 months the NEVO(TM) Sirolimus-eluting Coronary Stent has continued to demonstrate excellent safety and efficacy outcomes compared to Taxus(R) Liberte(R) according to new data presented today from the NEVO(TM) RES-I clinical trial. These results were presented as...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related